11/10/2017 - 06:32

PharmAust granted US patent for non-cancer uses of cancer drug

11/10/2017 - 06:32

Bookmark

Save articles for future reference.

ASX-listed biotech PharmAust has secured a patent in the US relating to the use of its promising anti-cancer drug Monepantel, for the treatment of non-cancerous conditions such as neurodegenerative diseases, diabetes and age-related illnesses. The patent is another move by Perth-based PharmAust to boost its global IP protections and follows the granting of patents in Europe, US, Australia and China.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options